Clinical Characteristics and Prognostic Analysis of Triple-negative Breast Cancer Patients

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2014 Mar 21

PMID 24649341

Citations 22

Authors

Na Yuan

Min Meng

Caigang Liu

Lu Feng

Lei Hou

Qian Ning

Guohong Xin

Li Pei

Shanzhi Gu

Xiao Li

Xinhan Zhao

Affiliations

Soon will be listed here.

Abstract

It is well-established that triple-negative breast cancer (TNBC) is a subtype of breast cancer, characterized by a poor prognosis and aggressive biological behavior. However, the available relevant data on TNBC in non-Western populations are limited. In order to analyze the clinicopathological and molecular biological characteristics and observe survival and prognostic factors, 972 breast cancer patients (156 of whom had TNBC) who received treatment at the First Affiliated Hospital of Medical School of Xi'an Jiaotong University and the First Hospital of China Medical University, between January, 2004 and January, 2007 were retrospectively evaluated. In the univariate analysis, tumor size, TNM stage, axillary lymph node status and recurrence or metastasis were identified as prognostic factors for 7-year disease-free survival (DFS) and overall survival (OS). Our multivariate Cox's regression analysis demonstrated that tumor size and axillary lymph node status were significant prognostic factors for 7-year DFS and OS. Notably, tumor subgroup (TNBC vs. non-TNBC) was a significant prognostic factor associated with 7-year DFS and OS in breast cancer. It was suggested that TNBC exhibited a worse 7-year survival compared with that in non-TNBC patients, most likely due to its more aggressive behavior and insensitivity to specific therapy.

Citing Articles

Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression.

Purwanto I, Leo B, Hutajulu S, Kurnianda J, Taroeno-Hariadi K, Hardianti M Breast Cancer (Dove Med Press). 2023; 15:515-524.

PMID: 37533591 PMC: 10390761. DOI: 10.2147/BCTT.S418696.

S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720.

Laroche F, Li S, Shen N, Hwang S, Nguyen G, Yu W Cells. 2023; 12(7).

PMID: 37048053 PMC: 10093541. DOI: 10.3390/cells12070980.

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype.

Ibragimova M, Tsyganov M, Litviakov N Cancers (Basel). 2021; 13(21).

PMID: 34771512 PMC: 8582512. DOI: 10.3390/cancers13215348.

Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer.

Purwanto I, Heriyanto D, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T World J Oncol. 2020; 11(5):216-222.

PMID: 33117465 PMC: 7575275. DOI: 10.14740/wjon1302.

Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.

Abdul Aziz A, Md Salleh M, Ankathil R Int J Breast Cancer. 2020; 2020:8424365.

PMID: 32308997 PMC: 7152932. DOI: 10.1155/2020/8424365.

References

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H . Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2011; 132(3):793-805. DOI: 10.1007/s10549-011-1554-7. View

Hicks D, Short S, Prescott N, Tarr S, Coleman K, Yoder B . Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006; 30(9):1097-104. DOI: 10.1097/01.pas.0000213306.05811.b9. View

Haffty B, Yang Q, Reiss M, Kearney T, Higgins S, Weidhaas J . Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24(36):5652-7. DOI: 10.1200/JCO.2006.06.5664. View

Nishimura R, Arima N . Is triple negative a prognostic factor in breast cancer?. Breast Cancer. 2008; 15(4):303-8. DOI: 10.1007/s12282-008-0042-3. View

Fadare O, Wang S, Hileeto D . The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?. Hum Pathol. 2008; 39(3):331-6. DOI: 10.1016/j.humpath.2007.07.014. View

Tischkowitz M, Brunet J, Begin L, Huntsman D, Cheang M, Akslen L . Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7:134. PMC: 1948892. DOI: 10.1186/1471-2407-7-134. View

Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I . Prognostic markers in triple-negative breast cancer. Cancer. 2006; 109(1):25-32. DOI: 10.1002/cncr.22381. View

Thike A, Cheok P, Jara-Lazaro A, Tan B, Tan P, Tan P . Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2009; 23(1):123-33. DOI: 10.1038/modpathol.2009.145. View

Reis-Filho J, Milanezi F, Steele D, Savage K, Simpson P, Nesland J . Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006; 49(1):10-21. DOI: 10.1111/j.1365-2559.2006.02467.x. View

10.

Yin W, Lu J, Di G, Lin Y, Zhou L, Liu G . Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat. 2008; 115(2):325-33. DOI: 10.1007/s10549-008-0096-0. View

11.

Kaplan H, Malmgren J, Atwood M . T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009; 15(5):454-60. DOI: 10.1111/j.1524-4741.2009.00789.x. View

12.

Minn A, Gupta G, Siegel P, Bos P, Shu W, Giri D . Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436(7050):518-24. PMC: 1283098. DOI: 10.1038/nature03799. View

13.

Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J . Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006; 66(9):4636-44. DOI: 10.1158/0008-5472.CAN-06-0031. View

14.

Zhang L, Hao C, Dong G, Tong Z . Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. Breast Care (Basel). 2012; 7(1):13-17. PMC: 3335351. DOI: 10.1159/000336539. View

15.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

16.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

17.

Shah S, Cope L, Poh W, Belton A, Roy S, Talbot Jr C . HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One. 2013; 8(5):e63419. PMC: 3642138. DOI: 10.1371/journal.pone.0063419. View

18.

Lin C, Chien S, Chen L, Kuo S, Chang T, Chen D . Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer. 2009; 9:192. PMC: 2706258. DOI: 10.1186/1471-2407-9-192. View

19.

Oakman C, Viale G, Di Leo A . Management of triple negative breast cancer. Breast. 2010; 19(5):312-21. DOI: 10.1016/j.breast.2010.03.026. View

20.

Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F . The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007; 16 Suppl 2:S72-7. DOI: 10.1016/j.breast.2007.07.017. View